The Delivery Challenge For In Vivo Cell Engineering
By Jyotsna Jajula, Research Assistant, Wayne State University
The rapid evolution of RNA technologies has fundamentally expanded what can be engineered within living cells. Programmable RNA therapeutics, CRISPR-based editors, and other nucleic acid payloads now enable precise control over gene expression, protein production, and cellular function. As these molecular tools become increasingly sophisticated, however, they have also exposed a critical limitation: therapeutic success depends not only on the performance of the cargo itself but also on the ability to deliver that cargo to the appropriate cells within the human body. Delivery has therefore become the critical determinant of whether advances in molecular engineering can be translated into effective therapies.1,3,10
This challenge is particularly evident in in vivo cell engineering, where therapeutic payloads must complete every stage of the engineering process within the complex biological environment of the human body. Unlike ex vivo approaches, which modify cells under controlled laboratory conditions before reinfusion, in vivo strategies require delivery systems to navigate systemic circulation, overcome biological barriers, selectively target specific cell populations, facilitate intracellular uptake, and achieve sufficient intracellular activity while maintaining an acceptable safety profile. Failure at any stage can compromise therapeutic efficacy regardless of the sophistication of the molecular payload.3,4,6
The clinical success of lipid nanoparticle-enabled mRNA therapeutics demonstrated that effective systemic delivery is achievable under defined biological conditions, accelerating interest in RNA-based therapies for increasingly diverse applications. Extending in vivo cell engineering beyond readily accessible tissues such as the liver to immune cells, hematopoietic stem cells, skeletal muscle, the lungs, or the central nervous system, however, presents distinct biological challenges that cannot be overcome by a single delivery strategy. As the field evolves, delivery is no longer simply a formulation challenge but a central engineering problem that will determine the precision, scalability, and clinical impact of next-generation RNA therapeutics.1,2
Why Delivery Remains The Primary Bottleneck
Advances in RNA engineering have dramatically increased the sophistication of therapeutic payloads while exposing delivery as the field's greatest remaining limitation. Improvements in messenger RNA design, genome-editing systems, and nucleic acid chemistry have expanded the scope of in vivo therapeutics. Unlike these molecular components, however, delivery cannot be optimized independently of its biological environment. Every therapeutic payload must function within a physiological system that shapes its distribution, cellular uptake, intracellular trafficking, and therapeutic activity.3,4,6
Successful delivery is not a single event but a sequence of interdependent biological processes. Therapeutic cargo must remain stable in circulation while avoiding degradation, immune recognition, rapid clearance, and off-target uptake. After reaching the target site, the delivery system must penetrate the extracellular environment, interact with target cells, undergo cellular internalization, escape endosomal sequestration, and release biologically active cargo. Because these barriers occur sequentially, failure at any stage can compromise therapeutic efficacy. Increasing tissue accumulation alone, for example, offers limited value if the cargo cannot enter the intended cells or reach the appropriate intracellular compartment.4,5
This challenge is evident across RNA therapeutic development. Lipid nanoparticles have achieved highly efficient hepatic delivery, contributing to the clinical success of several liver-targeted RNA medicines. Achieving comparable delivery to immune cells, hematopoietic stem cells, skeletal muscle, pulmonary tissue, or the central nervous system remains considerably more difficult. Each tissue presents distinct biological constraints defined by its vascular architecture, extracellular matrix, receptor expression, uptake mechanisms, and immune surveillance. Consequently, a strategy that performs well in one tissue often requires substantial redesign before succeeding in another.1,2,8
Delivery has therefore become a systems-level engineering challenge that extends far beyond formulation science. Success increasingly depends on the coordinated optimization of payload chemistry, carrier composition, targeting ligands, intracellular trafficking, manufacturability, and clinical dosing. These variables cannot be optimized independently because changes to one component influence biodistribution, cellular uptake, potency, tolerability, product stability, and overall therapeutic performance. Delivery is no longer merely an enabling technology for in vivo cell engineering; it is the defining factor determining whether sophisticated molecular designs become precise, scalable, and clinically meaningful therapies.3,6
One Delivery Strategy Cannot Fit Every Cell Type
The success of early RNA therapeutics, particularly those targeting the liver, initially suggested that broadly applicable delivery platforms might support diverse therapeutic applications. Experience has shown otherwise. The biological factors governing delivery vary substantially across tissues, meaning a strategy optimized for one target may perform poorly in another. No delivery system is universally effective; each must be designed around the physiological and cellular characteristics of its intended destination.1,2
The liver remains one of the most accessible targets for nanoparticle-based therapies because of its fenestrated vasculature, extensive blood perfusion, and natural role in clearing circulating materials. These features promote lipid nanoparticle accumulation and cellular uptake, contributing to the clinical success of several RNA medicines. Other tissues present distinct barriers. Skeletal muscle contains a dense extracellular matrix and requires broad distribution across large tissue volumes. The lungs contain mucus, specialized epithelial barriers, and active immune defenses, while the central nervous system is protected by the blood-brain barrier, which severely restricts the entry of systemically administered therapeutics. Hematopoietic compartments also contain diverse, often rare, cell populations that are difficult to access selectively.4,8,9
Target cell biology adds another layer of complexity. Hepatocytes, immune cells, muscle fibers, neurons, and hematopoietic stem cells differ in receptor expression, membrane composition, endocytic activity, intracellular trafficking, and cellular turnover. These differences determine not only whether a delivery system reaches and enters a cell but also whether the payload escapes intracellular compartments and reaches its site of action. High tissue accumulation may therefore coexist with poor functional delivery to the intended cell population.5,8
Successful development requires evaluating tissue-level distribution and cell-level activity as complementary but distinct challenges. Biodistribution studies identify where the carrier accumulates, whereas cell-specific analyses determine which populations internalize the payload and generate the intended molecular response. Functional assays must then confirm that delivery produces the desired biological effect rather than simply demonstrating uptake or transgene expression.3,8
These challenges are driving a shift away from universal platforms toward fit-for-purpose delivery systems. Such approaches may combine customized carrier chemistries, cell-selective ligands, optimized particle properties, engineered payloads, or alternative routes of administration. As therapeutic targets continue to diversify, successful delivery will increasingly depend on designing systems around the biology of the destination rather than the versatility of the carrier.
Engineering The Next Generation Of Delivery Systems
The recognition that no single delivery strategy can meet every therapeutic need has fundamentally changed how delivery technologies are developed. Rather than pursuing universal platforms, researchers are increasingly engineering systems that address the biological barriers of specific tissues, cell populations, and therapeutic objectives. This shift reflects a transition from platform-driven innovation to biology-informed design, in which the target determines the required properties of the delivery vehicle.1,2
Lipid nanoparticles remain the most clinically advanced nonviral delivery platform and continue to underpin many RNA therapeutics. Their success has demonstrated that carefully engineered carriers can achieve efficient intracellular delivery under favorable biological conditions. However, their limitations beyond hepatic applications have accelerated the development of alternative approaches. Polymeric nanoparticles, extracellular vesicles, virus-like particles, engineered viral vectors, and ligand-directed systems are being developed to improve tissue selectivity, intracellular trafficking, cargo capacity, repeat dosing, and immunological compatibility. Rather than competing technologies, these platforms offer complementary strengths that make them suitable for different biological contexts and therapeutic objectives.4,11
Improving delivery specificity is an equally important area of innovation. Advances in targeting ligands, receptor-mediated uptake, particle engineering, and nucleic acid chemistry are enabling systems that distinguish between cell populations rather than accumulating within an organ. This distinction is particularly important in heterogeneous tissues, where only a subset of cells requires modification. Consequently, developers must evaluate delivery specificity through functional cellular activity rather than tissue biodistribution alone.
Greater cellular specificity has the potential to improve therapeutic efficacy while reducing off-target activity, dose requirements, and treatment-related toxicity. However, targeting ligands alone do not ensure selective delivery. Ligand density, receptor expression, binding affinity, particle composition, serum protein interactions, and intracellular trafficking collectively determine whether targeting yields meaningful biological activity. These variables should therefore be evaluated as an integrated system, with functional studies confirming productive cargo release and the intended therapeutic response.3,8
Future delivery systems will likely integrate multiple design principles rather than rely on a single technological breakthrough. Carrier composition, particle architecture, targeting ligands, payload engineering, manufacturing, and routes of administration must function as coordinated elements of an integrated delivery strategy. Success will depend less on identifying a universally superior platform than on developing adaptable technologies optimized for their biological context. As therapeutic ambitions continue to expand, the most effective delivery systems will begin with the destination, not the carrier.3,6
The Future Of Delivery: From Carriers To Intelligent Systems
As the therapeutic scope of in vivo cell engineering expands, delivery systems must perform far more than molecular transport. Future platforms will need to navigate complex biological environments, reach specific cell populations, overcome intracellular barriers, and release payloads with the precision and consistency required for meaningful therapeutic benefit. The next generation of delivery technologies will therefore be defined not only by improved materials but also by increasingly sophisticated systems-level engineering.3,6
One emerging direction is the development of programmable delivery systems tailored to specific tissues, disease states, cell populations, and payloads rather than fixed platform architectures. Advances in carrier chemistry, particle engineering, ligand design, and nucleic acid modification are creating new opportunities to control biodistribution, cellular uptake, intracellular release, and duration of activity. Computational modeling, machine learning, and high-throughput screening may further accelerate formulation design by identifying relationships between material properties and biological performance that are difficult to uncover through conventional trial-and-error approaches.7,8
Future progress will also depend on solving challenges beyond delivery efficiency. Repeat dosing, manufacturing scalability, product consistency, long-term safety, and regulatory requirements will increasingly shape clinical translation. As RNA therapeutics expand into chronic diseases requiring repeated administration, delivery systems must maintain efficacy while minimizing cumulative toxicity, immune activation, and manufacturing variability. These considerations should be incorporated early rather than addressed during later stages of development.6,7
An intelligent delivery system should therefore encompass more than biological targeting. Its carrier composition, payload, targeting strategy, route of administration, dosing schedule, and manufacturing process must function as an integrated therapeutic system. A formulation that performs well in preclinical models but cannot be manufactured consistently, administered repeatedly, or translated across species is unlikely to achieve meaningful clinical impact.
Ultimately, the future of in vivo cell engineering will depend on the convergence of molecular biology, materials science, computational modeling, manufacturing, and clinical development. Rather than a universally superior carrier, progress will come from adaptable delivery systems engineered around the biological requirements, safety constraints, and therapeutic goals of each application.3,7
Conclusion
The rapid evolution of RNA engineering has transformed what is scientifically possible in cell and gene therapy. Programmable RNA therapeutics, genome-editing technologies, and increasingly sophisticated molecular payloads have expanded the potential of in vivo cell engineering. Yet designing powerful therapeutic cargo is no longer sufficient. Clinical success will increasingly depend on delivering these molecules to the right cells, in the right tissues, at the right time, and with the precision required to achieve meaningful therapeutic outcomes.
Meeting this challenge will require a broader view of delivery than simply selecting a carrier platform. Progress will depend on integrating molecular engineering, materials science, computational design, manufacturing, and clinical development into delivery strategies tailored to specific biological contexts. As therapeutic targets continue to diversify, the field must move beyond the search for a universal solution toward adaptable delivery systems designed around the requirements of each application.
The future of in vivo cell engineering will be shaped not only by increasingly sophisticated molecular payloads but also by equally sophisticated delivery systems. The greatest advances will come from delivery technologies that match the precision, programmability, and biological complexity of the therapeutics they are designed to carry.
References
1. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. doi:10.1038/s41578-021-00358-0
2. Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265-280. doi:10.1038/s41576-021-00439-4
3. Mendes BB, Conniot J, Avital A, et al. Nanodelivery of nucleic acids. Nat Rev Methods Primers. 2022;2:24. doi:10.1038/s43586-022-00104-y
4. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101-124. doi:10.1038/s41573-020-0090-8
5. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673-694. doi:10.1038/s41573-020-0075-7
6. Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017;2:17056. doi:10.1038/natrevmats.2017.56
7. Hanna AR, Issadore DA, Mitchell MJ. High-throughput platforms for machine learning-guided lipid nanoparticle design. Nature Reviews Materials. 2026;11:50-64. doi: 10.1038/s41578-025-00831-0
8. Hutchinson JA, Panda S, Rosales PD, Sowada JP, Willis MS, Leyden MC, Daoutidis P, Reineke TM. Guiding design and performance of nonviral nucleic acid delivery vehicles via machine learning. Advanced Drug Delivery Reviews. 2026;229:115739. doi: 10.1016/j.addr.2025.115739
9. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics, developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759-780. doi:10.1038/nrd4278
10. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines, a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279. doi:10.1038/nrd.2017.243
11. Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106(Pt A):148-156. doi:10.1016/j.addr.2016.02.006
12. Ginn SL, Amaya AK, Alexander IE, Edelstein ML, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018;20(5):e3015. doi:10.1002/jgm.3015
About The Author
Jyotsna Jajula is a research assistant at Wayne State University. Her work broadly explores RNA delivery mechanisms in oncology cell models, with a focus on internalization and cytoplasmic fate of therapeutic peptides. Jajula holds a master’s degree in pharmaceutical sciences and has prior research experience in lipid nanoparticles, RNA stability, and biodistribution strategies across oncology, immunology, and gene-therapy applications.